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The “master transcription factor” FOXP3 regulates the differentiation, homeostasis, and 
suppressor function of CD4+ regulatory T (Treg) cells, which are critical in maintaining 
immune tolerance. Epigenetic regulation of FOXP3 expression has been demonstrated 
to be important to Treg cell development, but the induction of human Treg cells through 
epigenetic modification has not been clearly described. We report that the combination 
of the DNA methyltransferase inhibitor 5-azacytidine (5-Aza) and suboptimal T cell 
receptor (TCR) stimulation promoted CD4+CD25hFOXP3+ T cell induction from human 
CD4+CD25− T cells. 5-Aza treatment enhanced the expression of Treg cell signature 
genes, such as CD25, FOXP3, CTLA-4, and GITR, in CD4+CD25h cells. Moreover, 
5-Aza-treated CD4+CD25h T cells showed potent suppressive activity in a cell contact-
dependent manner and reduced methylation in the Treg-specific demethylated region 
(TSDR) in the FOXP3 gene. The analysis of cytokine production revealed that CD4+CD25− 
T  cells with 5-Aza treatment produced comparable levels of interferon (IFN)-γ and 
transforming growth factor (TGF)-β, but less IL-10 and more IL-2, when compared to 
cells without 5-Aza treatment. The increased IL-2 was indispensible to the enhanced 
FOXP3 expression in 5-Aza-treated CD4+CD25h cells. Finally, 5-Aza-treated CD4+CD25h 
T cells could be expanded with IL-2 supplementation alone and maintained FOXP3 
expression and suppressor function through the expansion. Our findings demonstrate 
that DNA demethylation can enhance the induction of human Treg cells and promise to 
solve one of the challenges with using Treg cells in therapeutic approaches.
Keywords: immunological tolerance, human regulatory T cell, FOXP3, suboptimal Tcr stimulation, epigenetic 
regulation
inTrODUcTiOn
The subset of CD4+ T lymphocytes called regulatory T (Treg) cells have been demonstrated to 
prevent autoimmune disease and transplant rejection in human and experimental animal models 
(1, 2). Over the last decade, intense study of Treg cell gene expression, surface markers, and sup-
pressor function has revealed two Treg populations. Natural Treg (nTreg) cells are CD4+ T cells 
with strong T cell receptor (TCR) signaling that survive negative selection, develop, and mature 
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in the thymus. Adaptive Treg cells are induced in the periphery 
following specific tolerogenic stimulation (3). The forkhead 
winged-helix transcription factor FOXP3 has been shown to 
be critical for Treg cell differentiation and function. Ectopic 
expression of FOXP3 confers suppressive function and activates 
Treg cell signature genes, such as Il2ra (CD25), Ctla4 (CTLA-4), 
and Tnfrsf18 (GITR), in peripheral CD4+CD25− T cells (4, 5). 
Activation of human CD4+CD25− T cells through TCR stimula-
tion results in transient, low level expression of FOXP3 without 
conferring suppressive activity (6, 7), indicating that FOXP3 
must be constitutively expressed to maintain Treg cell function.
Various protocols have been developed to induce Treg cells 
from naive CD4+CD25− T cells. These include using a variety 
of APCs such as tolerogenic agent-treated DC (8–10) and 
plasmacytoid DC (11), cytokines such as transforming growth 
factor (TGF)-β (12) and IL-35 (13), and suboptimal antigenic 
activation (14). These efforts have produced FOXP3 expression 
and suppressor function of variable strength and stability. It 
has been reported that DNA demethylation in the foxp3 gene 
controls FOXP3 expression (15, 16) and the foxp3 methylation 
state discriminates bona fide Treg cells from activated FOXP3+ 
CD4+ T cells (17). Furthermore, several factors critical for 
Treg cell development, such as IL-2 receptor alpha chain (also 
called CD25) (18) and galectin-1 (19), are also regulated by the 
methylation of CpG islands in the respective promoter regions. 
These studies indicate that the induction of Treg cells in  vitro 
may be enhanced by modifying the ability of CD4+ T cells to 
demethylate DNA.
The typical inhibitor of DNA methyltransferase, 5-azacytidine 
(5-Aza), is a derivative of the nucleoside cytidine and approved 
by the FDA to treat myelodisplastic syndrome (MDS) (20). Some 
studies demonstrated that 5-Aza is capable of inducing strong 
expression of FOXP3 in mouse CD4+CD25− T cells (15, 16, 21, 
22). Similar results were also observed in human CD4+CD25− 
T cells (16, 23). However, these proposed 5-Aza-induced FOXP3+ 
T cells has not been fully characterized, and their functionality 
is controversial. The aim of the present study was to deter-
mine if 5-Aza treatment can promote the induction of human 
CD4+CD25hFOXP3+ T cells from CD4+CD25− T cells through 
suboptimal activation. Here, we show that the FOXP3 and other 
Treg cell-related markers, as well as the suppressor function of 
CD4+CD25h T cells, were enhanced by 5-Aza treatment, which 
triggered partial demethylation of Treg-specific demethylated 
region (TSDR) within the FOXP3 gene. The 5-Aza-treated 
CD4+CD25h T cells were hyporesponsive to TCR engagement 
and did not produce IL-2 after restimulation. Moreover, 5-Aza-
treated induced Treg cells could be expanded with exogenous 
IL-2 alone and retained FOXP3 expression and their suppressive 
activity after expansion.
MaTerials anD MeThODs
Blood samples
Adult peripheral blood obtained from healthy volunteers was 
acquired in accordance with the approval of Medical Ethics and 
Human Clinical Trial Committee of the Chung Gung Memorial 
Hospital. All subjects who were participated in this study gave 
written informed consent in accordance with the Declaration of 
Helsinki.
isolation of cD4+cD25− T cells
Peripheral blood mononuclear cells (PBMCs) were isolated by 
density gradient centrifugation over Ficoll-Paque (GE Healthcare) 
at 3000  rpm for 16  min. CD4+CD25− T cells were separated 
using a magnetic cell sorting (MACS) system (Miltenyi-Biotec). 
Briefly, CD4+ T cells were isolated from PBMCs by negative 
selection using an LD column. Purified CD4+ T cells were sub-
sequently incubated with anti-CD25 antibody-coated beads, and 
CD4+CD25− and CD4+CD25+ T cell fractions were separated by 
an MS column. The purity of isolated population was over 95% as 
determined by FACS analysis.
cell culture
CD4+CD25− T cells isolated from PBMC of healthy donors were 
cultured at 1 ×  106  cells/ml in RPMI1640 supplemented with 
2 mM l-glutamine, 1% pyruvate, 100 U/ml penicillin, 100 μg/ml 
streptomycin (Thermo Fisher Scientific), 50 μM 2-mercaptoetha-
nol (Sigma-Aldrich), and 10% heat-inactivated fetal bovine serum 
(FBS, GE Healthcare). The cells were activated by incubation with 
anti-CD2, anti-CD3, and anti-CD28 antibodies-coated beads 
(Miltenyi-Biotec) at a beads-to-cells ratio of 1:8 in the presence 
or absence of 5 μM 5-Aza (Sigma-Aldrich) for 4 days. For the 
examination of IL-2 effects on FOXP3 expression, neutralizing 
anti-human IL-2 and the isotype control antibodies (40 μg/ml) 
(Biolegend) were added to the cultures with 5-Aza treatment, 
respectively, at the beginning of the culture. Furthermore, 
recombinant human IL-2 (100  U/ml) (PeproTech) was also 
added to 5-Aza-untreated cultures. At the end of culture, cells 
were harvested for cellular characterization, and supernatants 
were collected for cytokine measurement.
Flow cytometric analysis
Harvested T cells were washed with 1× PBS (Sigma-Aldrich). 
The cell suspensions were then stained for 30 min at 4°C with 
the following mixtures of monoclonal antibodies (mAbs) against 
human antigens: (i) anti-CD4-FITC (clone PRA-T4), anti-CD25-
APC (clone BC96), and anti-GITR-PE (clone 621), anti-CTLA-
4-PE (clone BNI3), anti-HLA-DR-PE (clone L243), anti-LAP-PE 
(clone 27232), or anti-CD127-PE (clone hIL-7R-M21) and (ii) 
anti-CD4-PE (clone PRA-T4), anti-CD25-APC (Clone BC96), 
and anti-CD62L-FITC (clone DREG-56) or anti-CD134-FITC 
(clone ACT35). After staining, cells were washed and resuspended 
in 1× PBS. For intracellular FOXP3, perforin and granzyme B 
staining, cells were stained with anti-CD4-FITC and anti-CD25-
APC or anti-CD4-FITC and anti-CD25-PE (clone BC96) and 
were next processed with FOXP3/Transcription Factor Staining 
Buffer Set (eBioscience) according to the manufacturer’s instruc-
tions. Anti-FOXP3-PE (clone PCH101) or anti-perforin-PE 
(clone δG9) was added into cells stained with anti-CD4-FITC 
and anti-CD25-APC, and anti-granzyme B-Alexa Fluor 647 
(clone GB11) was added into cells stained with anti-CD4-FITC 
and anti-CD25-PE. Incubation was performed at 4°C for 30 min. 
For intracellular IL-2 staining, cells were restimulated with 
50 ng/ml PMA and 0.5 μg/ml ionomycin (Sigma-Aldrich) in the 
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presence of BD GolgiPlug (BD Biosciences) for 4 h before stain-
ing. After restimulation, cells were stained with anti-CD4-FITC 
and anti-CD25-PE followed by fixation and permeabilization as 
previous description. The cells were then incubated with anti-
IL-2-APC (clone MQ1-17H12) at 4°C for 30  min. Data were 
acquired on a FACSCalibur flow cytometer (BD Biosciences) 
and analyzed using the Cell-Quest software (BD Biosciences). 
Anti-CD4, anti-CD25, anti-CD62L, anti-GITR, anti-HLA-DR, 
and anti-IL-2 were purchased from Biolegend; anti-CD127, 
anti-CD134, anti-perforin, and anti-granzyme B were from BD 
Pharmingen; anti-CTLA-4 was from Serotec; and anti-FOXP3 
was from eBioscience.
cytokine Measurement
The concentration of IL-2, IL-10, interferon (IFN)-γ, and TGF-β 
in the culture supernatants were evaluated with ELISA kit (R&D 
Systems) according to the manufacturer’s instructions.
In Vitro suppression assay
Based on the expression intensity of CD25 molecule, CD25−, 
CD25dim, and CD25h (the expression intensity of CD25h was 
threefold higher than that of all CD25+ population) were sorted 
from 5-Aza-treated or 5-Aza-untreated T cells by FACSAria cell-
sorting system (BD Biosciences) to be suppressor cells. Freshly 
isolated CD4+ T cells designated as responder cells were stimu-
lated with anti-CD2, anti-CD3, and anti-CD28 antibodies-coated 
beads at a beads-to-cells ratio of 1:2 in 96-well round-bottom 
plates (5 × 104 cells/well). The different cell populations of sup-
pressor cells were added to the culture at responders-to-suppres-
sors ratios (R/S) of 1:1, 1:0.5, and 1:0.25 in the final volume of 
200 μl complete RPMI for 3  days. The wells were pulsed with 
1 μCi of 3H-thymidine (PerkinElmer) 16 h before harvesting. The 
results were measured with Topcount™ Microplate Scintillation 
and Luminescence Counter (Packard Instrument Company). 
For transwell assay, the responder cells were labeled with CFSE 
(5  μM, Thermo Fisher Scientific) for 10  min at 37°C. CFSE-
labeled responder cells were stimulated with anti-CD2, anti-CD3, 
and anti-CD28 antibodies-coated beads at a 1:2 beads-to-cells 
ratio in 24-well plates (2.5 × 105 cells/well). The suppressor cells 
were added to the culture at a 1:1 R:S ratio but separated from 
the responder cells by a Millicell insert (Millipore) for 3 days. The 
CFSE dilution was analyzed using a FACSCalibur cytometer.
rna isolation and mrna expression 
analysis
Total RNA was isolated from CD4+CD25− and CD4+CD25h cells 
that were sorted from 5-Aza-treated or 5-Aza-untreated T cells 
using a combination of TRIzol reagent (Thermo Fisher Scientific) 
and chloroform to purify the RNA. The quantity of RNA was 
determined by Nanodrop ND-1000 (Thermo Fisher Scientific). 
For cDNA synthesis, 1 μg of RNA was mixed with 10× reaction 
buffer and DNase I (Thermo Fisher Scientific) and incubated at 
37°C for 30  min. DNase I was inactivated by incubation with 
50-mM EDTA at 65°C for 10 min. The DNase I-treated RNA was 
then mixed with random hexamers (Thermo Fisher Scientific) 
and incubated at 70°C for 10 min. cDNA was synthesized with 
M-MLV Reverse Transcriptase (Thermo Fisher Scientific) at 37°C 
for an hour, and the reaction was inactivated at 70°C for 10 min. 
Real-time PCR was performed using SYBR Green PCR Master 
Mix (Thermo Fisher Scientific). RNA expression was measured 
using the following primers:
FOXP3 forward, 5′-CCCCTGGAGAGCCCAGCCAT-3′
FOXP3 reverse, 5′-GGCACAGCCGAAAGGGTGCT-3′
GAPDH forward, 5′-GAAGGTGAAGGTCGGAGTC-3′
GAPDH reverse, 5′-GAAGATGGTGATGGGATTTC-3′.
Dna extraction and Dna Methylation 
analysis
DNA was extracted from CD4+CD25h cells that were sorted from 
suboptimally activated T cells treated with or without 5-Aza, 
and CD4+CD25−CD127+ naive T cells and CD4+CD25hCD127− 
nTreg cells that were sorted from freshly isolated PBMCs 
using a GenElute Mammalian Genomic DNA Miniprep Kit 
(Sigma-Aldrich) according to the manufacturer’s instructions. 
For quantification of TSDR methylation, 500  ng of DNA was 
bisulfite-converted using a EpiTect Fast Bisulfite Conversion 
Kit (Qiagen) according to the manufacturer’s guidelines. 
The bisulfite DNA was used for two rounds of PCR using a 
PyroMark PCR Kit (Qiagen) with the following primers: for-
ward 5′-TTGTTGTAGGATAGGGTAGTTAGT-3′ and reverse 
Biotin-5′-CAACCCCCCACTTACCCAAATTTTT-3′. PCR was 
performed with the following parameters: denaturation at 95°C 
for 15 min, followed by 10 cycles at 95°C for 30 s, 62°C for 30 s, 
and 72°C for 30 s and another 40 cycles at 95°C for 30 s, 58°C for 
30 s, 72°C for 30 s, and the final elongation at 72°C for 7 min. The 
pyrosequencing procedure was performed on a PyroMark Q24 
(Qiagen) according to the manufacturer’s protocol, including 
the PCR product, PyroMark Gold Q24 reagents, binding buffer 
(Qiagen), Streptavidin Sepharose beads (GE Healthcare), and 
the sequencing primer 5′-AGGATAGGGTAGTTAGTT-3′. The 
methylation rate was determined by the PyroMark Q24 software.
cell lysate Preparation and 
immunoblotting
Naive CD4+CD25− T cells (1 × 106 cells/ml) with suboptimal TCR 
stimulation were treated with or without 5-Aza in the 24-well 
plate. Cells were harvested 4 days later and incubated with lysis 
buffer containing 0.1M NaCl, 20 mM Tris–HCl, 5 mM MgCl2, 
0.5% NP-40, and protease inhibitor (Sigma-Aldrich) on ice for 
30 min. Cell lysates were collected after centrifugation performed 
at 16,000 × g for 30 min at 4°C. The lysates were separated by 
8% SDS-PAGE and transferred to nitrocellulose membranes 
(GE Healthcare). Antibodies against DNMT1 (Santa Cruz) and 
β-actin (Sigma-Aldrich) were used to visualize the corresponding 
proteins.
statistical analysis
Statistical analyses were performed using Prism software 
(GraphPad). Mann–Whitney U test was used to compare all data. 
These data are presented as means ±  SD. P values <0.05 were 
considered statistically significant.
FigUre 1 | The treatment of 5-aza enhanced the expression of Treg-related markers. CD4+CD25− T cells were activated with anti-CD2/CD3/CD28 
antibody-coated beads at a bead-to-cell ratio of 1:8 in the presence or absence of 5-Aza for 4 days. (a,B) CD25 highly expressing cells were gated to examine 
the level of FOXP3, CTLA-4, and GITR expression by FACSCalibur. Considering high level of non-specific staining of FOXP3 antibody PCH101, FOXP3dim cells 
were excluded. One representative sample of nine experiments is shown. The results are shown as mean ± SD (*P < 0.05; **P < 0.01; ***P < 0.001).
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resUlTs
suboptimal Tcr stimulation combined 
with 5-aza Treatment induced More 
human cD4+cD25hFOXP3+ T cells from 
cD4+cD25− T cells
To investigate if DNA demethylation can enhance Treg cell induc-
tion, CD4+CD25− T cells isolated from PBMCs were stimulated 
with anti-CD2/CD3/CD28-coated beads at different bead-to-cell 
ratios in the presence or absence of 5-Aza for 4  days. Under 
suboptimal stimulation, 5-Aza-treated T cells expressed CD25 
at much higher levels compared to -untreated ones (Figure S1A 
in Supplementary Material). To confirm that CD25 expression 
correlated to Treg cells, we measured the levels of the Treg mas-
ter transcription factor FOXP3. FOXP3 expression was low in 
CD25dim cells and barely detectable in CD25− cells with or without 
5-Aza treatment (data not shown). The clone of the antibody we 
used to detect FOXP3 was PCH101, which has been reported 
to have high level of non-specific staining (24). Thus, we gated 
FOXP3h and excluded FOXP3dim cells for the analysis. In both 
treated and untreated CD4+CD25h T cells, FOXP3 expression 
was detected. Interestingly, treatment with 5-Aza increased the 
frequency of FOXP3+ cells, as well as the level of FOXP3 expres-
sion per cell (Figure 1A), suggesting inhibition of DNA meth-
yltransferase can enhance CD4+CD25hFOXP3+ T cell induction.
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Numerous surface markers have been discovered to be 
expressed on Treg cells, and many, such as CTLA-4 and GITR, 
have been implicated as crucial to their function. The percentages 
of CTLA-4 and GITR expressing cells were significantly increased 
in 5-Aza-treated CD4+CD25h T cells compared to -untreated 
counterparts (Figure  1B). Other Treg cell-related surface 
markers, such as CD62L, CD127, CD134, HLA-DR, and LAP, 
were expressed similarly between 5-Aza-treated and -untreated 
CD4+CD25h cells (Figure S1B in Supplementary Material). These 
data indicated that 5-Aza enhanced the expression of molecules 
essential to Treg cell development in human T cells with subop-
timal TCR stimulation.
5-aza-Treated cD4+cD25h T cells 
suppressed allogeneic cD4+ T cell 
activation
Hyporesponsiveness and the ability to suppress CD4+ T cells are 
definitive characteristics of Treg cells. To examine the response of 
5-Aza-treated and -untreated CD4+CD25h T cells, CD4+CD25h, 
CD4+CD25dim and CD4+CD25− T cells were sorted either from 
5-Aza-treated or -untreated T cells and re-activated with optimal 
TCR stimulation (Figure 2A). As expected, in both 5-Aza-treated 
and -untreated groups, CD4+CD25dim and CD4+CD25− T cells 
were highly proliferative when stimulated, while CD4+CD25h 
T cells showed much more diminished response. Remarkably, 
5-Aza-treated CD4+CD25h T cells exhibited weaker prolifera-
tion than -untreated CD4+CD25h T cells, suggesting that DNA 
methyltransferase inhibition can enhance the characteristic 
hyporesponsiveness of induced Treg cells.
To further investigate the effects of 5-Aza on the suppressor 
function of CD4+CD25h T cells, freshly isolated allogeneic CD4+ 
T cells, defined as responder cells, were optimally activated for 
3 days in the presence of 5-Aza-treated or -untreated CD4+CD25h 
T cells at the indicated ratios. Responder cells were more potently 
suppressed when cocultured with 5-Aza-treated CD4+CD25h 
than with 5-Aza-untreated CD4+CD25h T cells (Figure  2B). 
Neither CD4+CD25dim nor CD4+CD25− T cells exhibited any 
suppressive function themselves, irrespective of 5-Aza exposure 
(Figures S2A,B in Supplementary Material), strongly indicating 
that Treg cell induction can be greatly enhanced by inhibiting 
DNA methylation. Indeed, when comparing the suppressive abil-
ity of 5-Aza-treated CD4+CD25h T cells with that of nTreg cells, 
5-Aza-treated CD4+CD25h T cells showed stronger suppression 
at the R/S of 1/1 despite no statistical significance (Figure S3 in 
Supplementary Material).
It has been demonstrated that Treg cells exert their regula-
tory function through cell-to-cell contact in  vitro. We next 
used transwell assays to verify the inhibitory mechanism of 
5-Aza-treated CD4+CD25h T cell. CFSE-labeled responder cells 
expanded largely upon optimal TCR stimulation (Figure 2C). 
As expected, proliferation was dramatically hindered when 
responder cells were cocultured with 5-Aza-treated CD4+CD25h 
Treg cells. However, the suppression was abolished when 
the two cell populations were separated by a semi-permeable 
insert. Similarly, 5-Aza-treated CD4+CD25h Treg cells were able 
to suppress responder cell production of IL-2, although IL-2 
production did not recover completely when cell-to-cell contact 
was prevented (Figure  2D). After stimulation, 5-Aza-treated 
CD4+CD25h T cells, which we had previously demonstrated 
their hyporesponsive characteristic, did not produce IL-2 
(Figure  2D). Further examination of the molecules that have 
been proposed to determine Treg cell functionality revealed 
that perforin and granzyme B were dramatically upregulated 
in 5-Aza-treated CD4+CD25h Treg cells (Figure  2E). These 
data demonstrated the potential application of 5-Aza to induce 
human CD4+CD25− T cells into a population of CD4+CD25h 
T cells capable of regulating immune responses.
Partial Demethylation in the TsDr 
with increased foxp3 gene expression and 
Decreased level of DnMT1 Were 
Observed in 5-aza-Treated cD4+cD25h 
T cells
The TSDR in the foxp3 loci has been proposed to be hypomethyl-
ated in Treg cells. Demethylation within TSDR is not seen in 
activated T cells that transiently express FOXP3 (17, 25). To 
elucidate the effect of the methyltransferase inhibitor 5-Aza on 
Treg induction, we examined the foxp3 methylation pattern in 
T cells. Consistent with previous reports, we found that the 
TSDR was hypomethylated in nTreg but hypermethylated in 
naive T cells (Figure 3A). Partial demethylation was observed in 
5-Aza-treated CD4+CD25h cells, but the hypermethylated pattern 
was not changed in 5-Aza-untreated CD4+CD25h cells. To inves-
tigate the effect of demethylation by 5-Aza treatment on gene 
expression, we analyzed total RNA extracted from 5-Aza-treated 
and -untreated CD4+CD25h T cells. As shown in Figure 3B, foxp3 
was upregulated in 5-Aza-treated CD4+CD25h T cells compared 
to the 5-Aza-untreated cells. The expression of dnmt1, dnmt3a, 
and dnmt3b was also examined. They were expressed comparably 
between the 5-Aza-treated and -untreated cell populations (data 
not shown). Although the expression of dnmt family genes 
was not affected, we found that protein amounts of DNMT1 
were downregulated in 5-Aza-treated T cells, but not in their 
counterparts (Figure  3C). These data showed that decrease of 
DNA methylation in naive T cells through reduction of DNMT1 
by 5-Aza increased FOXP3 expression and potentiated their 
regulatory function.
il-2 Was indispensible to the enhanced 
FOXP3 expression in 5-aza-Treated 
cD4+cD25h T cells
Cytokines, such as IL-2 or TGF-β, have important effects on 
the development and function of Treg cells. We hence studied 
the cytokine production of suboptimally activated T cells under 
the influence of 5-Aza. As shown in Figure  4A, the level of 
IL-2 produced by 5-Aza-treated, suboptimally activated T cells 
was higher, but the level of IFN-γ was similar, compared to 
-untreated T cells. Next, we analyzed the levels of the inhibi-
tory cytokines IL-10 and TGF-β. The production of IL-10 was 
reduced when T cells were treated with 5-Aza, whereas that of 
TGF-β was comparable (Figure  4A). Since IL-2 is critical to 
FigUre 2 | 5-aza-treated cD4+cD25h T cells were hyporesponsiveness to Tcr stimulation and demonstrated potent suppressive function. 
(a) After suboptimal TCR stimulation under the influence of 5-Aza, CD4+CD25h, CD4+CD25dim, and CD4+CD25− T cells were sorted by FACSAria. The different cell 
populations were restimulated with antibody-coated beads at a bead-to-cell ratio of 1:2 for 3 days. Proliferation was determined at day 3, with [3H]-thymidine added 
for the last 16 h of culture. (B) Allogeneic CD4+ T cells (responder) were cocultured with CD4+CD25h T cells at the indicated ratios. Proliferation was also determined 
at day 3 with [3H]-thymidine addition. (c,D) The responder was incubated with CFSE first and cocultured with 5-Aza-treated CD4+CD25h T cells for 3 days. (–) and 
(+) represent cells without activation and cells stimulated with activation beads, respectively. The results were analyzed by FACSCalibur. Supernatants were collected 
for IL-2 measurement by ELIA. (e) After suboptimal TCR stimulation under the influence of 5-Aza, CD25 highly expressing cells were gated to examine the 
expression of perforin and granzyme B by FACSCalibur. Data are representative of seven independent experiments and shown as the mean ± SD (*P < 0.05).
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FigUre 3 | Treg-specific demethylating region in 5-aza-treated 
cD4+cD25h T cells is partially demethylated in company with higher 
foxp3 expression due to decreased DnMT1. (a) CD4+CD25h T cells 
were sorted from 5-Aza-treated and -untreated cells. Other cell 
populations were CD4+CD25−CD127+ and CD4+CD25hCD127−/low T cells 
sorted from CD4+ T cells which were separated from freshly isolated 
PBMCs. Genomic DNA was extracted, and the TSDR methylation 
pattern was analyzed by pyrosequencing. (B) RNA was extracted 
from CD4+CD25− and CD4+CD25h T cells, which were sorted from 
5-Aza-treated and -untreated cells for detection of foxp3, and GAPDH 
expression by real-time PCR. Data are representative of five independent 
experiments and shown as the mean ± SD (*P < 0.05; **P < 0.01; 
***P < 0.001). (c) Total proteins were extracted from 5-Aza-treated and 
-untreated cells for detection of DNMT1 and β-actin by western blot. One 
representative result of three experiments is shown.
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the development and maintenance of Treg cells, we tested to 
see if the increased IL-2 production from 5-Aza-treated cells 
might be important for their enhanced FOXP3 expression. We 
utilized anti-IL-2 antibody to neutralize IL-2 production in 
the culture with 5-Aza treatment. In addition, we examined 
whether exogenous IL-2 can augment FOXP3 expression 
by adding recombinant IL-2 to the culture without 5-Aza 
influence. As  shown in Figure  4B, IL-2 blockade eliminated 
the enhanced FOPX3 expression previously observed in 
5-Aza-treated CD4+CD25h T cells. However, exogenously sup-
plemented IL-2 did not augment FOXP3 expression in subop-
timally activated, 5-Aza-untreated CD4+CD25h T cells, which 
altogether suggested that IL-2 production was indispensable 
to the enhanced Treg induction effect of DNA demethylation. 
To further investigate the origin of IL-2 secretion, cultured cells 
were restimulated with PMA and ionomycin in the presence 
of GolgiStop. After restimulation, IL-2 was barely detectable 
in CD25h T cells irrespective of 5-Aza treatment. Surprisingly, 
the major population producing IL-2 was CD25dim T cells, 
which actually produced more IL-2 when they had been 
treated with 5-Aza (Figure  4C). These results demonstrated 
that 5-Aza treatment enhanced the induction of Treg cells 
from CD4+CD25− T cells directly by modifying FOXP3 protein 
expression in CD25h T cells as well as indirectly by increasing 
IL-2 production in CD25dim cells.
5-aza-Treated cD4+cD25h T cells 
Maintained FOXP3 expression and Their 
suppressive Function after 2-Week 
expansion with recombinant il-2 
supplement
The challenge to inducing Treg cells from human CD4+ T cells has 
been considered how to produce FOXP3+ T cells that maintain 
adequate suppressive function. To assess the ability of 5-Aza 
treatment to induce Treg cells, we examined FOXP3 expres-
sion and the suppressor function of 5-Aza-treated CD4+CD25h 
T cells after ex vivo expansion. Sorted 5-Aza-treated CD4+CD25h 
T cells were maintained in culture medium with 100  U/ml of 
recombinant IL-2 for 16  days. The medium was refreshed and 
supplemented with recombinant IL-2 (100 U/ml) every 2 days. 
The cell number was determined by trypan blue exclusion dur-
ing the every refreshment. 5-Aza-treated CD4+CD25h T cells 
expanded even if provided only with recombinant IL-2, as shown 
in the Figure 5A. Examination of FOXP3 expression indicated 
that 5-Aza-untreated CD4+CD25h T cells lost FOXP3 expression. 
Importantly, 5-Aza-treated CD4+CD25h T cells still retained 
FOXP3 expression (Figure 5B). Furthermore, expanded 5-Aza-
treated CD4+CD25h T cells were able to control the proliferation 
of responder cells in a dose-dependent manner (Figure  5C). 
These results indicated that 5-Aza-treated CD4+CD25h T cells 
retained FOXP3 expression and their ability to suppress after 
expansion with recombinant IL-2 alone.
DiscUssiOn
Ex vivo generation of Treg cells promises to revolutionize 
therapy for promoting tolerance post-transplantation and mod-
ulating the severity of autoimmunity and allergy. Heretofore, 
attempts to induce Treg cells from human CD4+ T cells have 
yet to produce stable FOXP3+ T cells capable of maintaining 
suppression. Activation thresholds have been proposed to be 
responsible for the peripheral tolerance (26), and suboptimal 
T-cell activation was found to promote induction of Treg cells 
in an autonomous TGF-β-dependent manner in murine sys-
tems (14, 27). In this study, we have demonstrated that DNA 
demethylation by 5-Aza can promote Treg cell induction by 
suboptimal TCR stimulation of human CD4+CD25− T cells 
through increasing IL-2 production in CD25dim and CD25− cells. 
The increased IL-2 synergistically enhanced FOXP3 expression 
in CD25h cells. Induced FOXP3+ T cells that had been treated 
with 5-Aza showed all the hallmarks of Treg cells, including 
expression of CTLA-4 and GITR, downregulated expression of 
CD127, production of TGF-β, and the capability of suppressing 
responder T-cells in a contact-dependent manner. Importantly, 
5-Aza-treated Treg cells could be expanded ex vivo with IL-2 
alone and maintained FOXP3 expression and their suppressive 
function after expansion.
Using DNA methyltransferase inhibitor to induce FOXP3 
expression has been extensively studied in mice (16, 22, 28). 
However, induction of FOXP3 expression with epigenetic modifi-
cation in human is still controversial. Lal and colleagues reported 
FigUre 4 | neutralization of il-2 which was majorly produced by cD25dim cells impeded the enhanced FOXP3 expression in cD25h cells treated with 
5-aza. CD4+CD25− T cells were activated with anti-CD2/CD3/CD28 antibody-coated beads at a bead-to-cell ratio of 1:8 in the presence or absence of 5-Aza for 
4 days. (a) IL-2, IFN-γ, IL-10, and TGF-β in the cultured supernatants were measured by ELISA. Data are representative of nine independent experiments. The 
results are shown as mean ± SD (*P < 0.05; **P < 0.01). (B) Neutralizing anti-IL-2 antibodies and recombinant IL-2 were added simultaneously to the cells treated 
with 5-Aza and without 5-Aza, respectively. FOXP3 was examined in the CD25h cells by FACSCalibur, and FOXP3dim cells were excluded. (c) After the incubation 
with 5-Aza, cells were restimulated with PMA and ionomycin for an hour followed by GolgiPlug treatment for another 3 h. Intracellular IL-2 was analyzed by 
FACSCalibur. One representative result of six (B) and three (c) experiments is shown.
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FigUre 5 | 5-aza-treated cD4+cD25h T cells proliferated without Tcr stimulation, but with only il-2 supplementation and still maintained FOXP3 
expression and their suppressive function after expansion. The sorted 5-Aza-treated CD4+CD25h T cells were cultured with recombinant IL-2 (100 U/ml). The 
culture medium supplied with IL-2 was refreshed every 2 days for 16 days. (a) The cell numbers were determined by trypan blue exclusion during the refreshment of 
the culture medium. (B) FOXP3 expression in the expanded CD4+CD25h T cells was examined by intracellular staining followed by flow cytometric analysis. 
FOXP3dim cells were excluded. (c) The expanded 5-Aza-treated CD4+CD25h T cells were cocultured with CFSE-labeled responder for 3 days. The results were 
analyzed by FACSCalibur. One representative result of five experiments is shown.
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that CD4+CD25+FOXP3+ T cells were induced from human 
CD4+CD25− T cells by the combination of 5-Aza-2′-deoxycytidine 
(5-Aza-dC) and TGF-β in the presence of exogenous IL-2, and 
they performed steady suppressive activity (16). Nevertheless, 
the resulting cells’ phenotype and regulatory function were not 
fully characterized. Furthermore, TGF-β-induced FOXP3+ cells 
in human system are still controversial (24, 29). We here show 
that the combination of suboptimal TCR stimulation and 5-Aza 
treatment induced a population of human CD4+ T cells that 
expressed higher level of CD25 and FOXP3 as well as CTLA-4 
and GITR when compared to the 5-Aza-untreated counterparts, 
and the amounts of TGF-β in the supernatants of 5-Aza-treated 
and -untreated groups were comparable, which might suggest the 
enhanced expression of CD25, FOXP3, CTLA-4, and GITR was 
TGF-β independent. Despite no significant difference compared 
to non-5-Aza-treated cells, downregulated expression of CD127 
in 5-Aza-treated CD4+CD25h T cells corresponded to the level in 
nTreg cells. Moreover, sorted 5-Aza-treated CD4+CD25h T cells 
not only were hyporesponsive to TCR engagement but also 
demonstrated potent suppressive activity in a contact-dependent 
manner, which are the two characteristics of nTreg cells observed 
in  vitro (30). It is worth mentioning that the strength of sup-
pression mediated by 5-Aza-treated CD4+CD25h T cells in vitro 
is comparable to that of nTreg cells. Still, before 5-Aza-treated 
CD4+CD25h T cells can be called “true” induced Treg cells, their 
transcription profile has to be compared to that of nTreg cells, 
and their suppressor function needs to be tested in  vivo in an 
immunological setting such as the xenogeneic graft-versus-host 
disease (GvHD) model in NOD-scid-γc− (NSG) mouse (31).
Demethylation of the CpG island in the Treg-specific 
demethylation region (TSDR) has been reported to promote 
stable and constitutive FOXP3 expression in nTreg cells (32, 
33). However, whether the TSDR is demethylated in the in vivo 
generated peripheral Treg (21, 34) and in vitro TGF-β-induced 
Treg (35–37) remains controversial. Despite only partial dem-
ethylation of the TSDR in 5-Aza-treated CD4+CD25h cells (but 
significantly reduced methylation), the level of foxp3 mRNA 
expression was increased when compared to the CD4+CD25h 
cells without 5-Aza treatment. In addition, the protein level of 
DNMT1 in 5-Aza-treated cells was decreased, in agreement with 
the fact that when 5-Aza incorporated into DNA forms covalent 
complexes with DNMTs, it results in the degradation of the 
enzymes (38). Recently, DNA demethylation enzymes, the Tet 
family members, have been proposed to be involved in regulating 
FOXP3 expression (39). We have examined the expression of Tet 
family members in 5-Aza-treated and -untreated CD4+CD25h 
T cells by real-time PCR. The expression of Tet1, Tet2, and Tet3 
was decreased in 5-Aza-treated CD4+CD25h T cells (data not 
shown), indicating that Tet proteins might not involve in the 
enhanced FOXP3 expression in cells treated with 5-Aza.
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A previous study reported by Kehrmann et al. indicated that 
5-Aza-dC reduced methylation within TSDR and increased 
FOXP3 expression in the 5-Aza-dC-treated CD4+CD25− cells, 
as well as the mRNA expression of T helper (Th)1-, Th2-, and 
Th17-related transcription factors (40). They found that the 
5-Aza-dC-treated cells did not suppress the proliferation of 
responder cells, suggesting the loss of suppressive ability of 
5-Aza-dC-treated cells despite the increased FOXP3 expression. 
In our opinion, the culture of CD4+CD25− T cells results in a 
heterogeneous cell population with varying CD25 expression. 
Isolation of CD25hFOXP3+ cells is necessary to study the role of 
5-Aza-dC treatment on Treg suppressive function. Furthermore, 
optimal TCR stimulation may trigger the differentiation of 
naive T cells into effector Th cell populations (41). Contrary 
to their study, we have demonstrated that sorted 5-Aza-treated 
CD4+CD25h T cells expressed important Treg cell markers, were 
not responsive to TCR stimulation, and showed potent suppres-
sive function. To address the concern that adult peripheral blood 
contains a large fraction of effector/memory CD4+ T cells, which 
are CD45RA−CD45RO+, the addition of CD45RA as a marker 
to select for pure naive CD4+ T cells could significantly raise the 
efficiency of Treg cell induction.
IL-2 signaling is critically required for the development and 
homeostasis of Treg cells for dominant immunotolerance in vivo 
(42). Previous studies also emphasized the important role of IL-2 
in the conversion of Treg cells from naive cells by TGF-β (37, 43). 
Our results demonstrated that IL-2 was increased in the 5-Aza-
conditioned culture. The IL-2 produced mainly by the CD25dim 
cells is indispensible to the enhanced expression of FOXP3 in 
CD25h cells. When blocking IL-2 by neutralizing antibodies, the 
expression of FOXP3 in 5-Aza-treated CD25h cells decreased 
to the FOXP3 level expressed by 5-Aza-untreated CD25h cells. 
Meanwhile, the addition of exogenous IL-2 to cells without 5-Aza 
treatment did not reinforce FOXP3 expression in CD25h cells, 
suggesting only suboptimal TCR stimulation is not sufficient 
to induce competent Treg cells. How the epigenetic changes 
provoked by 5-Aza requires IL-2 signaling in order to enhance 
FOXP3 expression in cells remains to be investigated.
To address concerns about the stability of Treg cell function 
which has been tightly correlated with the methylation status 
of foxp3 TSDR (3), we investigated whether 5-Aza-treated 
CD4+CD25h T cells could keep their suppressive ability. Sorted 
5-Aza-treated CD4+CD25h T cells were maintained in the 
culture medium supplemented with recombinant human IL-2 
for more than 2 weeks. IL-2 alone expanded the 5-Aza-treated 
CD4+CD25h T cells but for up to 20-folds. In addition, the 
5-Aza-treated CD4+CD25h T cells still maintained FOXP3 
expression and their suppressive ability after expansion. Taken 
together, we have demonstrated a simple and fast approach 
to induce human Treg cells in  vitro from CD4+CD25− T cells 
through the combination of suboptimal TCR stimulation and 
5-Aza treatment. 5-Aza-treated induced human Treg cells may 
be used as adoptive immunotherapy to alleviate the severity of 
diseases caused by unwanted immune reactions, such as allergy, 
autoimmune disease, transplant rejection, and GvHD.
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